Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-23-Speech-3-099"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Vote2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20021023.2.3-099"2
lpv:hasSubsequent	lp_eu:2002-10-23-Speech-3-1002
lpv:speaker	lp:Erik Meijer2
lpv:spokenAs	member; Committee on Regional Policy, Transport and Tourism (2002-01-17--2004-07-19)3 unknown; Socialistische Partij (1999-07-20--2004-07-19)3 member_of_the_bureau; EUL/NGL (1999-10-13--2004-07-19)3 member; Delegation to the EU-Slovak Republic Joint Parliamentary Committee (2002-02-07--2004-04-30)3 substitute; Delegation to the EU-Czech Republic Joint Parliamentary Committee (2002-02-07--2004-04-30)3 substitute; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3
lpv:translated text	". Medicines are commodities that earn money. This is why the assessment of their use stirs up so much emotion. Competing companies and competing methods benefit from legislation that results in companies selling as many of their own products as possible, thus pushing other products out of the market. They want over-consumption of their own products and the exclusion of alternatives. Unlike the Commission, the Committee on the Environment, Public Health and Consumer Policy opposes public advertising for medicines against AIDS, asthma and diabetes, and rightly so. Producers and users of alternative medicines, including doctors who prefer these products, fear that the proposed rules will, above all, benefit the chemical industry to the detriment of natural products. Some of these natural products are centuries-old remedies that work well according to their users, but whose effectiveness has never been scientifically proven. As long as they are not harmful and their composition is known, they deserve to be given the benefit of the doubt. Harmful and improper products that are only produced to make money should be banned, but there is no reason for granting the pharmaceutical industry a monopoly position. I therefore vote against the industry's proposals and in favour of those that are advocated by groups of doctors and users."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph